Clinical trial of lamivudine in children with chronic hepatitis B. by Jonas, M.M. et al.
 The New England Journal  of  Medicine
 
1706
 
·
 
N Engl J Med, Vol. 346, No. 22
 
·
 
May 30, 2002
 
·
 
www.nejm.org
 
CLINICAL TRIAL OF LAMIVUDINE IN CHILDREN WITH CHRONIC HEPATITIS B
 
M
 
AUREEN
 
 M. J
 
ONAS
 
, M.D., D
 
EIRDRE
 
 A. K
 
ELLEY
 
, M.D., J
 
ACEK
 
 M
 
IZERSKI
 
, M.D., I
 
SABEL
 
 B. B
 
ADIA
 
, M.D., 
J
 
ORGE
 
 A. A
 
REIAS
 
, M.D., K
 
ATHLEEN
 
 B. S
 
CHWARZ
 
, M.D., N
 
ANCY
 
 R. L
 
ITTLE
 
, B.S., M
 
ARTIN
 
 J. G
 
REENSMITH
 
, P
 
H
 
.D., 
S
 
TEPHEN
 
 D. G
 
ARDNER
 
, M.S.P.H., M. S
 
TEVE
 
 B
 
ELL
 
, B.S
 
C
 
., 
 
AND
 
 E
 
TIENNE
 
 M. S
 
OKAL
 
, M.D., 
 
FOR
 
 
 
THE
 
 I
 
NTERNATIONAL
 
 P
 
EDIATRIC
 
 L
 
AMIVUDINE
 
 I
 
NVESTIGATOR
 
 G
 
ROUP
 
*
 
A
 
BSTRACT
 
Background
 
Lamivudine therapy is effective for
chronic hepatitis B infection in adults. We evaluated
the efficacy and tolerability of lamivudine as a treat-
ment for chronic infection with hepatitis B virus
(HBV) in children.
 
Methods
 
Children with chronic hepatitis B were
randomly assigned in a 2:1 ratio to receive either oral
lamivudine (3 mg per kilogram of body weight; max-
imum, 100 mg) or placebo once daily for 52 weeks.
The primary end point was virologic response (de-
fined by the absence of serum hepatitis B e antigen
and serum HBV DNA) at week 52 of treatment.
 
Results
 
Of the 403 children screened, 191 were ran-
domly assigned to receive lamivudine and 97 to re-
ceive placebo. The rate of virologic response at week
52 was higher among children who received lamivu-
dine than among those who received placebo (23 per-
cent vs. 13 percent, P=0.04). Lamivudine therapy was
well tolerated and was also associated with higher
rates of seroconversion from hepatitis B e antigen to
hepatitis B e antibody, normalization of alanine amino-
transferase levels, and suppression of HBV DNA. 
 
Conclusions
 
In children with chronic hepatitis B,
52 weeks of treatment with lamivudine was associ-
ated with a significantly higher rate of virologic re-
sponse than was placebo. (N Engl J Med 2002;346:
1706-13.)
 
Copyright © 2002 Massachusetts Medical Society.
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HRONIC hepatitis B is a widespread dis-
ease that affects more than 350 million
people worldwide, or approximately 5 per-
cent of the world’s population.
 
1
 
 Typically,
the virus is actively replicating in infected children,
as demonstrated by the presence of hepatitis B e an-
tigen (HBeAg) in serum and high serum levels of
hepatitis B virus (HBV) DNA. The course of the
disease varies, and it may result in spontaneous viral
clearance, prolonged latency, or progressive damage
to the liver. Those who become infected early in life
are at highest risk for chronic infection, cirrhosis,
and hepatocellular carcinoma.
 
2,3
 
Therapeutic options for adults with chronic hep-
atitis B include the nucleoside analogue lamivudine
(Epivir-HBV, GlaxoSmithKline) and the cytokine in-
terferon alfa. Interferon alfa therapy is cumbersome
C
 
to deliver, is uncomfortable to receive, and has unde-
sirable side effects. Since the rates of success of lamiv-
udine therapy among adults are similar to those of in-
terferon therapy, we undertook the present study to
assess the safety and efficacy of lamivudine treatment
in children with chronic hepatitis B.
 
METHODS
 
Study Design 
 
This randomized, double-blind, placebo-controlled study was
conducted between September 1998 and July 2000 at 40 centers
in North America, South America, and Europe. The academic in-
vestigators actively participated in the design of the study and the
interpretation of results. The sponsor held the data, but all inves-
tigators had full access to them. The writing, review, and final ap-
proval of the manuscript were performed by a committee of 11
persons, including 4 representatives from the research and devel-
opment departments of GlaxoSmithKline.
Children who completed the trial were stratified on the basis
of HBeAg status at 48 weeks and offered either open-label lamiv-
udine treatment or observation for an additional 2 years. Data
from the first six months of the open-label study are available.
 
Patients
 
Eligibility requirements included an age between 2 and 17 years
at enrollment, seropositivity for hepatitis B surface antigen (HBsAg)
for at least 6 months before enrollment, seropositivity for HBeAg,
undetectable levels of antibody against HBeAg (anti-HBe), serum
alanine aminotransferase values that were more than 1.3 times the
upper limit of the normal range (but less than 500 IU per liter) for
at least 3 months before enrollment, evidence of inflammation on
liver biopsy,
 
4
 
 and measurable HBV DNA in serum on branched-
chain DNA assay (Chiron/Bayer Quantiplex assay, version 1, with
a lower limit of detection of 0.7 meq per milliliter).
Patients were excluded if they had received interferon within the
previous 12 months or systemic antiviral agents, immunomodula-
tory drugs, cytotoxic agents, or corticosteroids within the previous
6 months. Patients were also excluded if they were coinfected with
the human immunodeficiency virus, hepatitis C virus, or hepatitis
D virus or they had decompensated liver disease, renal insufficien-
cy, pancreatitis, a clinically significant coexisting medical illness, or
other types of liver disease. Women who were pregnant or breast-
feeding were excluded. Liver biopsy to determine eligibility had
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to have been performed within 24 months before enrollment and
at least 12 months after the completion of interferon therapy (for
patients who had received interferon).
Patients or their parents or legal guardians provided written in-
formed consent using a form approved by the appropriate insti-
tutional review board or ethics committee. We compared lamivu-
dine with placebo, since there were no approved treatments for
chronic hepatitis B in children when the trial was initiated.
 
Treatment
 
Randomization was performed at a central location. Patients
were randomly assigned (in a 2:1 ratio) to receive either lamivu-
dine solution at a dose of 3 mg per kilogram of body weight (max-
imal dose, 100 mg) or a matching placebo solution orally once dai-
ly for 52 weeks.
 
5
 
Clinical and Virologic Procedures
 
Patients were assessed two, four, and eight weeks after the ini-
tiation of therapy, every eight weeks until week 48, and at week
52. Blood samples were drawn at each visit to monitor blood
chemical and hematologic values. Female patients with childbear-
ing potential were required to have a pregnancy test at every study
visit. During the 52-week study, investigators and patients were un-
aware of the results of HBV DNA and HBsAg assays. The result of
the HBeAg assay was disclosed at week 48 and used for stratifica-
tion at week 52 for the follow-up study. Commercially available en-
zyme-linked immunoassays were used to measure HBeAg, anti-
HBe, HBsAg, and antibody against HBsAg (anti-HBs) (HBe
[rDNA] Enzyme Immunoassay, AxSym HBe Microparticle En-
zyme Immunoassay, HBs Auszyme Enzyme Immunoassay, and
Ausab Enzyme Immunoassay, respectively; all from Abbott Labo-
ratories). All samples were analyzed at a central reference laborato-
ry (Covance Clinical Laboratory Services); however, prothrombin
times were determined at each center, and genotypic analysis for
resistance mutations was performed at GlaxoSmithKline Virology
Laboratories. Serum samples collected at base line and week 52
were frozen at –80°C for subsequent genotypic analysis for resist-
ance mutations. Mutations in the YMDD (tyrosine, methionine, as-
partate, and aspartate) motif of the reverse-transcriptase domain in
the HBV polymerase gene were assessed by the polymerase chain
reaction and restriction-fragment–length polymorphism assay.
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An independent histopathologist who was unaware of the pa-
tients’ treatment assignments assessed liver-biopsy specimens ob-
tained before treatment using the Knodell Histologic Activity In-
dex.
 
4
 
 Scores for this index can range from 0 (normal) to 22 (severely
abnormal) and represent the sum of four histologic components:
the severity of periportal necrosis (range of scores, 0 to 10), intra-
lobular necrosis (range of scores, 0 to 4), portal inflammation
(range of scores, 0 to 4), and fibrosis (range of scores, 0 to 4).
 
Efficacy Assessments
 
All assessments of efficacy were based on data obtained after 52
weeks of treatment. The primary efficacy end point was virologic re-
sponse, a composite measure defined by the loss of serum HBeAg
and by the reduction of serum HBV DNA to undetectable levels —
changes indicative of a durable remission.
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 Secondary end points
included sustained normalization of the alanine aminotransferase
values (at least two consecutive values below the upper limit of the
normal range without any subsequent abnormality through the end
of therapy); seroconversion from HBeAg to anti-HBe, with or
without the disappearance of HBV DNA; the loss of HBeAg; the
loss of HBsAg; and the absence of detectable levels of HBV DNA
in serum. Follow-up liver biopsy was not part of the protocol.
 
Safety Assessments
 
All patients were assessed for adverse events at each visit. Levels
of alanine aminotransferase, albumin, bilirubin, amylase, lipase, cre-
atine kinase, hemoglobin, white cells, neutrophils, and platelets
were assessed. Weight and height were measured.
 
Statistical Analysis
 
All analyses were prespecified. On the basis of similar studies of
adults with chronic hepatitis B, we estimated that the rates of viro-
logic response would be 25 percent among children in the lamivu-
dine group and 9 percent among children in the placebo group.
Given these estimated response rates, we calculated that 255 pa-
tients (170 in the lamivudine group and 85 in the placebo group)
would be required for the study to have 80 percent power to detect
an absolute difference between groups of 17 percent at an alpha
level of 0.05. This sample size would also give the study 90 percent
power to identify an absolute difference between groups of 34 per-
cent with respect to the proportion of patients with the secondary
end point of sustained normalization of alanine aminotransferase
values.
We used a modified intention-to-treat analysis, which included
all patients with confirmed chronic hepatitis B who were assigned
to either treatment group, to assess efficacy. For the primary end
point of virologic response, as well as for the secondary end points,
patients who withdrew before week 52 or for whom data were miss-
ing at week 52 were considered to have had no response. All sta-
tistical tests (chi-square, Fisher’s exact, and Wilcoxon rank-sum)
for comparisons between treatment groups and resulting P values
were two-sided.
For the analysis of safety, we analyzed the data according to the
treatment received. We included all patients who were randomly
assigned to either treatment group and who received at least one
dose of study medication.
We used logistic-regression models to assess whether there were
treatment-related differences in the rate of virologic response after
adjustment for the following base-line factors: score on the Histo-
logic Activity Index, alanine aminotransferase level, HBV DNA lev-
el, age, sex, racial or ethnic origin, body-mass index, weight, and
presence or absence of cirrhosis. Logistic regression was also used
to examine the differences between groups according to whether
the patients had previously received interferon therapy and whether
they had YMDD-variant HBV DNA.
 
RESULTS
 
Study Population
 
The numbers of patients who were screened, un-
derwent randomization, withdrew from the study,
and were analyzed are presented in Figure 1. There
were no significant differences in demographic char-
acteristics between the treatment groups (further in-
formation is available as Supplementary Appendix 1
with the full text of this article at http://www.nejm.
org). Although at base line, the median alanine ami-
notransferase value (2.3 vs. 2.1 times the upper limit
of the normal range) and HBV DNA level (1032 vs.
895 meq per milliliter) tended to be higher in the
placebo group than in the lamivudine group, these
differences were not statistically significant. Forty-
five percent of the children had had no response to
interferon therapy, and the proportions were similar
in the lamivudine group and the placebo group (47
percent and 42 percent, respectively).
 
Pretreatment Liver Biopsy
 
Evaluations of liver-biopsy specimens obtained be-
fore treatment indicated that, although the median
The New England Journal of Medicine 
Downloaded from nejm.org at CENTRO HOSPITALAR DE COIMBRA on March 2, 2011. For personal use only. No other uses without permission. 
 Copyright © 2002 Massachusetts Medical Society. All rights reserved. 
 1708
 
·
 
N Engl J Med, Vol. 346, No. 22
 
·
 
May 30, 2002
 
·
 
www.nejm.org
 
The New England Journal  of  Medicine
 
total scores on the Histologic Activity Index and the
median scores for necrosis and inflammation were sim-
ilar in the two groups, the mean scores were higher in
the placebo group than in the lamivudine group (Ta-
ble 1). The range of scores was wide in both groups,
however, and some children had severe disease with
clinically significant fibrosis. Three patients had cirrho-
sis (two assigned to receive lamivudine and one as-
signed to receive placebo).
 
Efficacy
 
A virologic response had occurred by week 52 in
23 percent of children in the lamivudine group, as
compared with 13 percent of children in the placebo
group (44 of 191 vs. 12 of 95; odds ratio, 2.1; 95
percent confidence interval, 1.0 to 4.1; P=0.04) (Ta-
ble 2). The median time to the normalization of ala-
nine aminotransferase levels in the lamivudine group
was 24 weeks (Fig. 2A). The rate of virologic response
increased with increasing base-line alanine amino-
transferase values (Fig. 2B). Only 2 of the 44 pa-
tients in the lamivudine group who had a virologic
response did not have detectable anti-HBe at week
52. However, in both patients, this antibody had
been present at week 48 and was present again one
month after treatment.
Logistic-regression analyses demonstrated that
higher base-line alanine aminotransferase values and
scores on the Histologic Activity Index were associ-
ated with a greater likelihood of virologic response.
After adjustment for these factors, a logistic-regres-
sion model confirmed that the difference between
lamivudine and placebo was significant (adjusted
odds ratio, 3.89; 95 percent confidence interval,
1.66 to 9.08; P=0.002). The adjusted odds ratios
and confidence intervals associated with various po-
tential prognostic factors are presented in Table 3.
Logistic-regression analysis showed that there were
no significant differences in the rates of virologic re-
sponse and normalization of alanine aminotransferase
 
Figure 1.
 
 Numbers of Patients Included in or Excluded from Randomization and Subsequent Analyses.
97 Assigned to placebo
m1 Did not receive placebo
mm(withdrew consent before
mmreceiving first dose)
4 Withdrew from study
m2 Lost to follow-up
m1 Withdrew consent
m1 Had adverse event
95 Included in analysis conducted 
maccording to a modified
mintention-to-treat principle
mm2 Had unconfirmed chronic 
mmmhepatitis
96 Included in analysis according 
mto treatment actually received
403 Assessed for eligibility
191 Assigned to lamivudine
6 Withdrew from study
m2 Lost to follow-up
m2 Withdrew consent
m1 Had adverse event
m1 Was noncompliant with therapy
191 Included in analysis 
mconducted both according to a 
mmodified intention-to-treat 
mprinciple and according to 
mtreatment actually received
288 Randomized
115 Excluded
m109 Did not meet inclusion or
mmexclusion criteria
m006 Reason unknown
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values between children who had previously received
interferon and those who never received interferon.
 
Safety
 
The nature, incidence, and severity of adverse
clinical events and abnormal laboratory values in pa-
tients receiving lamivudine were similar to those in
patients receiving placebo (see Supplementary Ap-
pendix 2 with the full text of this article at http://
www.nejm.org). There were no deaths during the
study. The incidence and extent of elevations in ala-
nine aminotransferase values were similar in the two
groups. In no patient was the alanine aminotransfer-
ase value elevated in association with hyperbilirubi-
nemia or other signs of hepatic decompensation.
There was no significant difference between the
lamivudine group and the placebo group in the change
in the weight-for-age z scores from base line to week
52 (P=0.75). The median changes were 0.01 (range,
¡1.11 to 3.35) in the lamivudine group and 0.12
(range, ¡1.69 to 0.98) in the placebo group. Height-
for-age z scores were calculated at the time of screen-
ing and at week 48; there was no significant difference
between groups in the change in the height-for-age
z score (P=0.61): the median change was 0.01 (range,
¡1.68 to 2.81) in the lamivudine group and 0.05
(range, ¡0.84 to 1.9) in the placebo group.
 
Analysis of HBV Genotypic Resistance
 
Serum samples were available for genotypic analy-
sis from 90 percent of patients in the placebo group
(86 of 96) and 87 percent of patients in the lamivu-
dine group (166 of 191) at week 52. HBV DNA from
19 percent of patients in the lamivudine group (31 of
166) had detectable codon changes at site 552 (me-
thionine to valine or isoleucine) in the C domain of
the YMDD motif of the HBV polymerase gene. Dem-
ographic characteristics were similar between patients
with YMDD-variant HBV DNA and patients with
 
*Liver biopsies were performed up to 24 months before enrollment in the
study and at least 12 months after the completion of interferon therapy (in
patients who had received interferon therapy). Scores for the Histologic Ac-
tivity Index can range from 0 (normal) to 22 (severely abnormal) and are the
sum of four histologic components: the severity of periportal necrosis (range
of scores, 0 to 10), intralobular necrosis (range of scores, 0 to 4), portal in-
flammation (range of scores, 0 to 4), and fibrosis (range of scores, 0 to 4).
†P values were calculated with use of a Wilcoxon rank-sum test.
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Total score
Median
Range
Mean ±SD
4
0–13
5.7±2.7
4
0–12
4.7±2.2 0.002
Necrosis–inflammation score
Median
Range
Mean ±SD
3
0–10
4.3±2.1
3
0–9
3.5±1.7 0.002
Fibrosis score
Median
Range
Mean ±SD
1
0–4
1.4±0.9
1
0–4
1.2±0.8 0.035
*CI denotes confidence interval, anti-HBe hepatitis B e antibody, HBeAg hepatitis B e antigen,
HBV hepatitis B virus, and HBsAg hepatitis B surface antigen.
†P values were calculated with the use of the chi-square test.
‡A virologic response was defined by the absence of HBeAg and HBV DNA in serum.
§Only patients with base-line alanine aminotransferase levels that exceeded the upper limit of the nor-
mal range were included in the analysis (88 in the placebo group and 183 in the lamivudine group).
¶Levels were undetectable on branched-chain DNA assay with a lower limit of detection of 0.7
meq per milliliter.
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no. (%)
 
Virologic response‡ 12 (13) 44 (23) 2.1 (1.0–4.1) 0.04
Sustained normalization of alanine 
aminotransferase level§
11 (12) 100 (55) 8.4 (4.2–16.9) <0.001
Virologic response and acquisition 
of anti-HBe
12 (13) 42 (22) 1.9 (1.0–3.9) 0.06
Loss of HBeAg 14 (15) 50 (26) 2.1 (1.1–3.9) 0.03
HBV DNA undetectable¶ 15 (16) 117 (61) 8.4 (4.5–15.7) <0.001
Loss of HBsAg 0 3 (2) — —
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the wild-type sequence. The median serum HBV
DNA level tended to be higher at base line in the
patients in whom the YMDD variant was present at
52 weeks (Table 4). Median alanine aminotransfer-
ase values, bilirubin levels, and scores for the Histo-
logic Activity Index were similar in these two sub-
groups. 
HBeAg disappeared during the study in only one
child in whom the YMDD-variant HBV DNA was
present at week 52. This child had anti-HBe and
normal alanine aminotransferase values at week 52.
However, the median HBV DNA level in the 31
children with variant HBV was substantially lower at
week 52 than at base line (Table 4). Among these
patients, 29 percent had HBV DNA levels at week
52 that were below the limit of detection of a con-
ventional assay and were measurable only by the
polymerase chain reaction. Ninety-one percent of
patients with detectable levels of HBV DNA at week
52 (20 of 22) had levels that were lower than the
 
Figure 2.
 
 Median Alanine Aminotransferase Values during the 52-Week Treatment Period (Panel A) and
Rates of Virologic Response According to the Base-Line Alanine Aminotransferase Value (Panel B).
A virologic response was defined by the absence of hepatitis B e antigen and hepatitis B virus DNA in
serum at 52 weeks. In Panel A, not all patients were evaluated at each follow-up visit. The dotted line
indicates the upper limit of alanine aminotransferase values. In Panel B, values in parentheses are the
number of patients with a response and the total number of patients with a base-line alanine amino-
transferase value in that range.
0
«1 >1 to «2 >2 to «5 >5
60
50
40
30
20
10
Alanine Aminotransferase Value
(no. of times the upper limit of the normal range)
Placebo
Lamivudine
Placebo
Lamivudine
V
ir
o
lo
g
ic
 R
es
p
o
n
se
 (
%
)
0.0
2.5A
B
0 52
2.0
1.5
1.0
0.5
4 8 16 24 32 40 48
Weeks
NO. EVALUATED
Placebo
Lamivudine
96
191
95
182
95
188
92
182
95
186
94
182
91
182
93
185
91
183
M
ed
ia
n
 A
la
n
in
e 
A
m
in
o
tr
an
sf
er
as
e
V
al
u
e 
(n
o
. o
f 
ti
m
es
 t
h
e 
u
p
p
er
lim
it
 o
f 
th
e 
n
o
rm
al
 r
an
g
e)
14%
(1/7)
12%
(1/8) 7%
(2/30)
12%
(10/86)
12%
(5/41)
31%
(25/81) 24%
(4/17)
50%
(8/16)
The New England Journal of Medicine 
Downloaded from nejm.org at CENTRO HOSPITALAR DE COIMBRA on March 2, 2011. For personal use only. No other uses without permission. 
 Copyright © 2002 Massachusetts Medical Society. All rights reserved. 
 LAMIVUDINE FOR CHRONIC HEPATITIS B IN CHILDREN
 
N Engl J Med, Vol. 346, No. 22
 
·
 
May 30, 2002
 
·
 
www.nejm.org
 
·
 
1711
 
base-line level. The median alanine aminotransferase
value was also lower at week 52 than at base line in
children with YMDD-variant HBV DNA (Table 4);
the levels were normal in 45 percent (14 of 31).
 
Follow-up Study
 
During the first six months of open-label treat-
ment with lamivudine, a virologic response occurred
in an additional 10 percent of patients (12 of 123)
who had previously been assigned to receive lamivu-
dine. Among patients who were merely observed
during follow-up because they had had a virologic
response in the first year of treatment, 82 percent
(33 of 40) had a sustained response. Patients who had
had a response to lamivudine during the first year
were as likely to have a sustained response as those
who had had spontaneous clearance of HBeAg and
HBV DNA.
 
DISCUSSION
 
This international study of children with chronic
hepatitis B demonstrated that 52 weeks of treatment
with lamivudine resulted in a higher rate of virologic
response than did 52 weeks of placebo. The second-
ary end points of virologic response with the devel-
opment of anti-HBe and undetectable levels of HBV
DNA and normalization of serum alanine amino-
transferase values were also more frequent in lamiv-
udine-treated children. These results are consistent
with those in adults with chronic hepatitis B.
 
8-11
 
The average base-line alanine aminotransferase lev-
el and Histologic Activity Index score were higher in
the placebo group, the latter significantly so. Since
these factors have been associated with a virologic
response in this and other studies, there may have
been an intrinsic bias favoring placebo that would
have minimized the differential effects of lamivudine.
Preparations of interferon alfa have been approved
for the treatment of chronic hepatitis B in children.
Although generally safe and effective, interferon has
substantial limitations, including the need for re-
peated injections for six months, undesirable side ef-
fects such as growth impairment,
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 and a low rate of
efficacy in patients with serum HBV DNA levels
above 200 pg per milliliter or only minimally elevat-
ed levels of alanine aminotransferase.
 
13-16
 
 Our study
included patients who had had no response to inter-
feron therapy, and the rate of virologic response of
23 percent in the lamivudine group was similar to
the rate of 26 percent reported with interferon ther-
 
*Odds ratios were adjusted for base-line alanine aminotransferase values and base-line Histologic
Activity Index score and are based on a logistic-regression model that included the treatment assign-
ment and the factor of interest. CI denotes confidence interval, and HBV hepatitis B virus.
†Scores for the Histologic Activity Index can range from 0 (normal) to 22 (severely abnormal) and
are the sum of four histologic components: the severity of periportal necrosis (range of scores, 0 to
10), intralobular necrosis (range of scores, 0 to 4), portal inflammation (range of scores, 0 to 4), and
fibrosis (range of scores, 0 to 4).
‡Subgroup analyses indicated an interaction between HBV DNA level and treatment, so the P val-
ue for this factor should be interpreted with caution.
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DJUSTED ODDS RATIOS FOR VIROLOGIC RESPONSE TO LAMIVUDINE 
ASSOCIATED WITH POTENTIAL PROGNOSTIC VARIABLES.*
VARIABLE
LAMIVUDINE
GROUP
(N=191)
ADJUSTED
ODDS RATIO
(95% CI)
P
VALUE
no./total no. (%)
Base-line alanine aminotransferase
Twice the upper limit of the normal range or less
More than twice the upper limit of the normal range
11/94  (12)
33/97  (34)
1.0
3.41 (1.75–6.66)
<0.001
Histologic Activity Index score†
0–4
5–9
10–14
12/113 (19)
20/53  (38)
2/7  (29)
1.0
1.77 (0.95–3.29)
2.57 (0.81–8.17)
0.002
Base-line HBV DNA
<800 meq/ml
»800 meq/ml
30/93  (32)
14/98  (14)
1.0
0.25 (0.13–0.49)
0.04‡
Racial or ethnic origin
White
Asian
Other
29/139 (21)
10/33  (30)
5/19  (26)
1.0
1.27 (0.61–2.66)
1.05 (0.40–2.76)
0.54
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apy in children.17 These results were achieved despite
the fact that the median base-line levels of alanine ami-
notransferase were higher in the interferon study than
in our study. As is the case with interferon, the rates
of virologic response to lamivudine were higher with
higher base-line levels of alanine aminotransferase.
The emergence of YMDD-variant HBV may reverse
the response in some patients and has been considered
a limitation of lamivudine therapy. This variant was
detected in 19 percent of patients who received lamiv-
udine for 52 weeks, as compared with 16 to 32 per-
cent of adults in other studies.8-11 In these other stud-
ies, few adults with YMDD-variant HBV had lost
HBeAg after one year of treatment. In some instances,
liver disease may progress with continued treatment
in patients with persistent viremia who have YMDD-
variant HBV. However, long-term trials have indicat-
ed that seroconversion can still occur with extended
treatment and that the presence of YMDD-variant
HBV DNA does not necessarily signify a complete
loss of efficacy or preclude HBeAg seroconversion.18
We found that the frequency of HBeAg responses was
substantially lower with continued treatment but that
the HBV DNA and alanine aminotransferase levels re-
mained below base-line values in the majority of pa-
tients with YMDD-variant HBV, suggesting that
the replicative ability of these viral variants was de-
creased.19,20 The optimal duration of treatment in chil-
dren in whom YMDD-variant HBV develops has not
been established, and longer-term follow-up is war-
ranted.
We found that treatment of chronic hepatitis B with
lamivudine for one year is safe in children and is su-
perior to placebo, although neither approach is highly
efficacious. Efficacy may be improved by selecting
patients whose alanine aminotransferase value is at
least twice the upper limit of the normal range. Pre-
liminary data suggest that virologic and biochemical
responses achieved with lamivudine therapy are as du-
rable as spontaneous responses, at least for the first six
months. Although there are interim data to suggest
that further therapeutic responses are achieved with
longer therapy, the development of genotypic resist-
ance may limit the benefits of extended therapy, since
the long-term outcome of chronic hepatitis B in chil-
dren with lamivudine-resistant mutants is unknown.
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ber of the company’s Hepatitis National Advisory Board.
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APPENDIX
In addition to the authors, the International Pediatric Lamivudine Inves-
tigator Group includes the following: E.M. Alonso, Children’s Memorial
Hospital, Chicago; F. Alvarez, Hopital Ste.-Justine, Montreal; W. Balistreri,
Children’s Hospital Medical Center, Cincinnati; F. Bortolotti, Policlinico
Universitario, Padua, Italy; J. Cabral, Hospital de D. Estefania, Lisbon, Por-
tugal; H.S. Conjeevaram, University of Chicago Hospitals and Clinics, Chi-
cago; K.F. Crissinger, Vanderbilt University School of Medicine, Nashville;
G. Ferreira, Hospital Fernando da Fonseca, Amadora, Portugal; J.F.
Fitzgerald, James Whitcomb Riley Hospital for Children, Indianapolis;
D.A. Gremse, University of South Alabama, Mobile; H.I. Hann, Jefferson
Medical College, Philadelphia; P. Harmatz, Children’s Hospital Oakland,
Oakland, Calif.; P. Jara, Ciudad Sanitaria La Paz, Madrid; S. Karyda, Ip-
pokration General Hospital, Thessaloniki, Greece; J.D. Lewis, Children’s
Center for Digestive Healthcare, Atlanta; E. Maller, Children’s Hospital of
Philadelphia, Philadelphia; N. Manolaki, Agia Sophia Children’s Hospital,
Athens, Greece; P. Mohan, Children’s National Medical Center, Washing-
ton, D.C.; K.F. Murray, Children’s Hospital and Medical Center, Seattle;
*Analyses for the YMDD (tyrosine, methionine, aspartate, and aspartate) motif were performed at
base line and week 52 in 166 patients in the lamivudine group; the variant was found only at week 52.
TABLE 4. MEDIAN LEVELS OF HEPATITIS B VIRUS (HBV) DNA AND 
ALANINE AMINOTRANSFERASE, ACCORDING TO THE PRESENCE OR ABSENCE 
OF A MUTATION IN THE YMDD MOTIF.*
VARIABLE
NO. OF 
PATIENTS HBV DNA ALANINE AMINOTRANSFERASE
BASE LINE WEEK 52 BASE LINE WEEK 52
meq/ml
no. of times the upper limit
of the normal range
YMDD variant absent
Median
Range
135
753.2
2.2–28,300
0.35
0.35–2604
2.0
0.7–16.9
0.8
0.2–3.7
YMDD variant present
Median
Range
31
1648
158.5–13,018
6.75
0.35–1217
2.2
1.3–5.5
1.2
0.4–5.4
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Schreiber, British Columbia Children’s Hospital, Vancouver, B.C., Canada;
W. Sluzewski, Klinika Obserwacyjno, Poznan, Poland; R. Sokol, Children’s
Hospital, Denver; R. Squires, Children’s Medical Center of Dallas, Dallas;
N. Tassopoulos, Western Attica General Hospital, Athens, Greece; T. Tor-
mo, Hospital Infantil Valle de Hebron, Barcelona, Spain; W.R. Treem,
Duke University Medical Center, Durham, N.C.; P. Vajro, University of
Naples, Naples, Italy; S. Weisdorf, Fairview University Medical Center,
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